Human IFNα2A and α2B, a combination of IFNα2A, B, and C, as well as a synthetic designer molecule based on the consensus of different IFNα subtypes, IFNβ and IFNγ have been approved by the FDA to treat different infectious diseases (see http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). This evidence concerns the gene IFNA2 and infectious disease.